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CCR1 blockade reduces interstitial inflammation and fibrosis
in mice with glomerulosclerosis and nephrotic syndrome.
Background. CC chemokines mediate leukocyte infiltration
into inflamed tissue. We have recently shown that blockade of
the CC chemokine receptor CCR1 reduces interstitial inflam-
mation and fibrosis in murine obstructive nephropathy. How-
ever, it is not known whether CCR 1 blockade is protective in
progressive renal injury associated with severe proteinuria. We
therefore studied the effect of the small-molecule CCR1 an-
tagonist BX471 in a murine model of adriamycin-induced focal
segmental glomerulosclerosis (FSGS) with nephrotic syndrome
and progressive interstitial inflammation and fibrosis.
Methods. Adriamycin nephropathy with persistent protein-
uria was induced in male BALB/c mice by two intravenous in-
jections of adriamycin (13 mg/kg) at day 0 and 14. BX471 treat-
ment was started at day 14 when proteinuria and interstitial
inflammation had developed. At 6 weeks, renal histology was
studied by morphometry and immunohistochemistry.
Results. At week 6, adriamycin-treated mice showed FSGS,
associated with tubulointerstitial injury consisting of tubu-
lar dilation and atrophy, interstitial leukocyte infiltration,
and fibrosis. The mRNA expression of CCR1 and CC
chemokines, including the CCR1 ligands CCL3 (MIP-1a)
and CCL5 (RANTES), was up-regulated in diseased kidneys,
with a prominent interstitial expression of CCL5. Compared
to vehicle-treated controls BX471 significantly reduced the
amount of macrophages and T lymphocytes in interstitial lesions
by 51% and 22%, respectively. Markers of renal fibrosis such
as interstitial fibroblasts (48%) and interstitial volume (23%)
were significantly reduced by BX471 treatment. In contrast, the
extent of proteinuria and glomerular sclerosis was not affected
by BX471 treatment.
Conclusion. Blockade of CCR1 substantially reduced inter-
stitial leukocyte accumulation and the subsequent renal fibro-
sis in a murine model of nephrotic syndrome and FSGS. These
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findings support a role for CCR1 in interstitial leukocyte recruit-
ment and suggest that CCR1 blockade might be a new thera-
peutic strategy in progressive nephropathies such as FSGS.
Regardless of etiology, glomerulosclerosis and tubu-
lointerstitial fibrosis are the final common pathways
of progression seen in most chronic renal diseases
[1]. Glomerulosclerosis is characterized by increased
glomerular matrix accumulation and collapse of the cap-
illary lumina. Initially, this process may affect only some
glomeruli (focal), with only part of the glomerular tuft
involved (segmental), leading to the characteristic histol-
ogy seen in focal segmental glomerulosclerosis (FSGS)
[2]. The structural alterations in the glomerulus are ac-
companied by sustained proteinuria, often of nephrotic
range. Associated with progressive glomerulosclerosis
are tubular atrophy and dilation, interstitial inflammatory
infiltrates, accumulation of interstitial fibroblasts, and in-
creased matrix deposition, which ultimately lead to inter-
stitial fibrosis and loss of renal function [1, 2]. The inter-
stitial recruitment of macrophages and lymphocytes as
a major source of inflammatory and profibrotic media-
tors plays an important role in chronic interstitial inflam-
mation and fibrosis [3, 4]. Independent of the primary
glomerular lesion it is the severity of this tubulointersti-
tial damage and the degree of interstitial leukocyte infil-
tration that correlates best with the loss of renal function
and the risk for progression to end-stage renal disease
(ESRD) [4, 5]. Therapeutic strategies to prevent or de-
lay loss of organ function in chronic renal disease must
therefore target pathways instrumental in the fibrotic tis-
sue remodeling.
Locally secreted chemokines trigger leukocyte
adhesion to activated endothelium and subsequent
infiltration into inflamed tissue [6, 7]. Human renal
biopsy data and an expanding number of animal studies
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suggest that the expression of chemokine receptors on
the surface of leukocytes infiltrating the glomerulus or
tubulointerstitium are functional in the initiation and
progression of renal disease [8–10]. The CC chemokine
receptor CCR1 is expressed on circulating monocytes
and lymphocytes, and has been consistently found
to be up-regulated in a variety of progressive renal
disease models [9, 10]. We have recently shown that
blockade of CCR1 with the small-molecule antago-
nist BX471 (5-chloro-2-(2-[(2R)-4-(4-fluorobenzyl)-
2-methylpiperazin-1-yl]-2-oxoethoxy phenyl) urea
hydrogen chloride salt) reduced interstitial leukocyte
infiltration and renal fibrosis in murine obstructive
nephropathy [11]. An important role of CCR1-positive
leukocytes in mediating tissue fibrosis has also been
demonstrated in a pulmonary fibrosis model in mice [12].
In contrast, genetic targeting of CCR1 increased the
severity of glomerulonephritis in knockout mice given
nephrotoxic serum [13]. Thus, it is not known, whether
CCR1 blockade is protective in the progression phase
of chronic nephropathies (e.g., established glomerular
disease with severe proteinuria and secondary interstitial
damage). To investigate whether therapeutic CCR1
antagonism affects the course of glomerulosclerosis and
interstitial fibrosis BX471 was studied in murine adri-
amycin nephropathy, a model of FSGS with persistent
proteinuria and interstitial inflammation [14]. In this
report, we demonstrate that CCR1 and its ligands CCL3
(MIP-1a) and CCL5 (RANTES) are up-regulated in
adriamycin nephropathy. Blocking CCR1 with BX471
reduced interstitial inflammation and fibrosis, but did
not alter glomerular pathology and proteinuria. Our
results suggest that CCR1 blockade is an effective
therapeutic approach to slow progression to ESRD in
chronic proteinuric nephropathies, even if the primary
glomerular pathology is not attenuated.
METHODS
Animals
Male inbred BALB/c mice weighing 22 to 25 g and aged
8 weeks were obtained from Charles River (Sulzfeld,
Germany) and kept in macrolone type III cages under
a 12-hour light and dark cycle. Water and standard chow
(Sniff, Soest, Germany) were available ad libitum. All ex-
perimental procedures were performed according to the
German animal care and ethics legislation and had been
approved by the local government authorities.
Experimental design
To induce progressive glomerulosclerosis and
tubulointerstitial inflammation in mice we adapted
a previously described protocol [14]. Mice received two
intravenous tail vein injections of 13 mg/kg body weight
adriamycin at day 0 and 14. This induced persistent
proteinuria throughout the study period of 6 weeks,
associated with chronic glomerular and tubulointerstitial
lesions as seen in human FSGS. Initial dose-finding
experiments revealed that, in our hands, a single dose of
11 mg/kg adriamycin induced transient proteinuria only,
with a peak at day 14 and complete remission between
4 and 6 weeks. With this regimen histology at 6 weeks
showed minimal glomerular changes and no interstitial
pathology. A single dose of 13 mg/kg adriamycin resulted
in a more severe, but still transient proteinuria, with
inconsistent and highly variable histologic results at
week 6. Injection of 15 mg/kg adriamycin was associated
with high mortality.
Eight groups of mice were studied. In a first set of ex-
periments mice were injected with a matched volume of
isotonic saline (group 1) or with 13 mg/kg adriamycin
(2 mg/mL doxorubicin hydrochloride) (Pharmacia & Up-
john, Erlangen, Germany) on day 0 and 14 (group 2). To
test the effect of BX471 adriamycin-treated mice were
additionally dosed subcutaneously with either 50 lL of
vehicle solution (group 3) or 50 mg/kg BX471 in 50 lL
vehicle solution (group 4) at 8-hour intervals. Two addi-
tional control groups received isotonic saline instead of
adriamycin, and were treated subcutaneously with 50 lL
of vehicle solution (group 5) or 50 mg/kg BX471 (group
6) at 8-hour intervals. Treatment with vehicle or BX471
was started at day 14, when proteinuria had developed in
adriamycin-injected mice, and was given throughout the
study until week 6. To assess glomerular and interstitial
pathology at week 2, before BX471 treatment was started,
additional saline (group 7) and adriamycin-injected mice
(group 8) were sacrificed for renal histology and immuno-
histochemistry at week 2. In each experiment five to seven
mice per group were examined. A detailed evaluation of
the antagonistic properties, dosing and pharmacokinetics
of BX471 in mice has been published [11]. The vehicle so-
lution (40% cyclodextrin) (Sigma-Aldrich, Deisenhofen,
Germany) and BX471 were prepared as previously de-
scribed [11].
Renal functional parameters
Spot urine samples were obtained from each mouse
at day 0 and at 2-week intervals thereafter until week
6. Urine albumin concentrations were determined by a
double-sandwich enzyme-linked immunosorbent assay
(ELISA) [15]. The 96-well plates were coated overnight
with 5 lg/mL of an affinity-purified goat antimouse albu-
min monoclonal antibody (Bethyl Laboratories, Mont-
gomery, TX, USA) diluted in 0.05 mol/L carbonate
buffer, pH 9.5. Wells were blocked with phosphate-
buffered saline (PBS) containing 0.05 mL/100 mL of
Tween 20 and 0.5% bovine serum albumin (BSA) (both
from Sigma-Aldrich). After washing three times with
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PBS/Tween serial dilutions of samples or standard (10 to
1000 ng/mL of mouse serum albumin) (Sigma-Aldrich)
in blocking solution were added for 2 hours at room
temperature. Plates were washed three times, and wells
were incubated for 2 hours at room temperature with
horseradish peroxidase–labeled goat antimouse albumin
antibody (Bethyl Laboratories) diluted in blocking so-
lution. Bound secondary antibody was detected with
o-phenylenediamine (Sigma-Aldrich) as the substrate.
Absorbance was read at 490 nm with a microtiter
plate reader. Urinary creatinine was quantitated spec-
trophotometrically with a commercially available kit
(Sigma-Aldrich). Albumin excretion was expressed as
microgramms of urinary albumin per milligram of uri-
nary creatinine.
Blood from retro-orbital venous plexus sampling was
collected from each animal at the end of the study period
(week 6). Serum values for blood urea nitrogen (BUN),
total protein, albumin, and cholesterol were obtained
with a Hitachi autoanalyzer (Hitachi, Tokyo, Japan).
Renal morphology and immunohistochemistry
From each mouse cranial kidney halves were used for
histologic assessment. Tissue was fixed in 10% neutral-
buffered formalin, dehydrated in graded alcohols and
embedded in paraffin. For routine histology and mor-
phometric analysis 4 lm coronal sections were stained
with hematoxylin and eosin, periodic acid-Schiff (PAS)
reagent, and silver following the instructions of the
supplier (Bio-Optica, Milano, Italy). For immunohis-
tochemistry sections were deparaffinized, rehydrated,
transferred into citrate buffer, and either autoclaved or
microwave treated for antigen retrival. Sections were
blocked with 3% H2O2, avidin, and biotin (Vector Block-
ing Kit) (Vector Laboratories, Burlingame, CA, USA) for
20 minutes each. After washing in PBS, slides were incu-
bated with the primary antibody for 1 hour at room tem-
perature. Monoclonal rat antibodies were used to stain
for leukocytes (antimouse CD45, 1:200) (BD Pharmin-
gen, San Diego, CA, USA), macrophages (ER-HR3 [16],
1:100) (BMA Biomedicals, Augst, Switzerland), and T
lymphocytes (a cross-reacting antihuman CD3 antibody,
1:100) (Serotec, Oxford, UK). Activated fibroblasts were
stained with a polyclonal antiserum (1:1000) against re-
combinant murine fibroblast-specific protein 1 (FSP1)
generated in a New Zealand white rabbit as described
elsewhere [17]. For mRANTES/CCL5 a polyclonal rabbit
antimouse antibody (PeproTech, Rocky Hill, NY) (1:50)
was used. To detect murine monocyte chemoattractant
protein-1 (mMCP-1)/CCL2, a custom antipeptide anti-
serum against mMCP-1 was raised in rabbits as previ-
ously described [18]. Signals of all primary antibodies
were detected with a commercial mouse link and label
kit following the instructions of the supplier (BioGenex
SuperSensitive) (BioGenex, San Ramon, CA, USA). 3-
amino-9-ethylcarbazole (AEC) substrate was used for
signal development, and sections were counterstained
with hemalaun. As negative controls for immunohisto-
chemistry primary antibodies were omitted or replaced
with species-matched control antibodies with irrelevant
specificity.
Histomorphometric analysis
The degree of glomerulosclerosis was assessed by
computer-aided image analysis of PAS-stained kidney
sections. Under a light microscope (Leitz DMR) (Le-
ica Microsystems, Bensheim, Germany) at ×400 magni-
fication, 20 randomly selected glomerular cross-sections
per mouse were captured with a digital camera (Leica
DC300) (Leica Microsystems) connected to the micro-
scope. Quantitative analysis of the pictures was per-
formed by using the Adope PhotoShop version 6.0
software, which allows counting of specifically stained
pixels [19]. The outline of the glomerular tuft was traced,
and the number of pixels within the outline was used as
a measure of total gomerular area. The area covered by
PAS-positive staining in the same glomerulus was deter-
mined by counting the pixels of PAS-specific red color.
The degree of glomerulosclerosis for each glomerulus
was calculated as percentage of specific colored pixels
per total number of glomerular pixels. Interstitial vol-
ume expansion within interstitial lesions was quantitated
as recently described [11]. Briefly, an interstitial volume
index was determined by superposing a grid containing
100 (10 × 10) sampling points on pictures of 20 nonover-
lapping fields (×200) of silver-stained tissue per animal.
The number of points overlaying interstitial space were
counted and expressed as percentage of all points. Accu-
mulation of leukocytes and fibroblasts within interstitial
lesions was analyzed by counting positive cells in 20 high
power fields (×400) per mouse. Analyses were performed
by operators unaware of the origin of each kidney section.
RNA preparation and renal chemokine expression
The lower half of each kidney was snap frozen in liquid
nitrogen and stored at −80◦C. Total RNA was prepared
using the method of Chomczynski and Sacci [20]. Renal
chemokine expression was analyzed using a ribonuclease
protection assay (RPA). A RiboQuant multiprobe tem-
plate set for murine chemokines (mCK5) was obtained
from BD Pharmingen. Transcription of antisense ribo-
probes with a32P-uridine triphosphate (UTP) (3000 Ci/
mmol) (NEN, Cologne, Germany), hybridization and
RNase treatment was performed according to the man-
ufacturer’s instructions. RNase protected hybridization
products were separated on a 6% denaturating poly-
acrylamide gel. The intensity of the specific bands was
quantitated using a Molecular Dynamics Storm 840
PhosphorImager (Molecular Dynamics, Sunnyvale, CA,
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USA) and a standard software program (ImageQuant)
and normalized to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) gene expression.
For in situ hybridization single-stranded 35S-labeled
riboprobes for mMCP-1/CCL2 and mRANTES/CCL5
were prepared by in vitro transcription of subcloned
cDNA fragments, and hybridization was performed on
4 lm sections of paraffin-embedded renal tissue as previ-
ously described [18, 21].
Real-time quantitative reverse transcription-polymerase
chain reaction (RT-PCR) for CCR1
CCR1 mRNA expression was determined in saline-
or adriamycin-treated kidneys (week 6). In addition,
CCR1 expression was analyzed in isolated leukocyte
populations and cultured intrinsic renal cells. Splenic
macrophages and T cells from BALB/c mice were
obtained with an immunomagnetic cell seperation
technique. Spleens were dissociated into single cell sus-
pensions. Macrophages were labeled with a fluores-
cein isothiocyanate (FITC)-conjugated rat anti-mouse
F4/80 antibody (1:75) (Serotec) and isolated after incuba-
tion with paramagnetic anti-FITC MicroBeads (Miltenyi
Biotec, Bergisch Gladbach, Germany) using separation
columns (Miltenyi Biotec) according to the manufac-
turer’s instructions. CD4+ T cells were seperated using
anti-CD4 MicroBeads (Miltenyi Biotec). Cell purity af-
ter separation was verified to be >95%, and viability
assessed by trypan blue exclusion was >90%. For iso-
lation of primary renal fibroblasts small pieces of renal
tissue from BALB/c mice were incubated in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen Corpo-
ration, Karlsruhe, Germany) supplemented with 10%
heat-inactivated fetal calf serum (FCS) (Invitrogen) and
1% penicillin-streptomycin (DMEM-C10) for 21 days.
Adherent cells were lifted with 1.5 mmol/L ethylene-
diaminetetraacetic acid (EDTA) and were depleted for
leukocytes by immunomagnetic selection using FITC
antimouse CD45 (BD Pharmingen) and anti-FITC Mi-
croBeads (Miltenyi Biotec). A tubular epithelial cell
line, mouse cortical tubular (MCT cells) [22] was main-
tained in DMEM-C10. Cell cultures were incubated for
12 hours without supplements before stimulation or stan-
dard medium for 24 hours. Tubular epithelial cells were
stimulated with 0.1 lg/mL lipopolysaccharide (LPS) for
8 hours, renal fibroblasts with 1 ng/mL transforming
growth factor-b (TGF-b) for 8 hours.
Total renal RNA or RNA isolated from cell lines
were treated with DNase I (Qiagen, Hilden, Germany).
Two micrograms of RNA underwent random primed
reverse transcription for 1 hour at 42◦C using a modified
Moloney murine leukemia virus reverse transcriptase
(Superscript) (Life Technologies, Karlsruhe, Germany).
Negative control samples were prepared by performing
the latter reaction in the absence of reverse transcrip-
tase (RT- control). Real-time RT-PCR was performed
on a TaqMan ABI 7700 Sequence Detection System
(PE Biosystems, Weiterstadt, Germany) using a heat-
activated TaqDNA polymerase (Amplitaq Gold) (PE
Biosystems) as described [18]. Controls consisting of
ddH2O were negative for target or housekeeping genes.
The following oligonucleotide primers (300 nmol/L) and
probes (100 nmol/L) were used: 5′-TTAGCTTCCATGC
CTGCCTTATA-3′ (sense), 5′-TCCACTGCTTCAGGC
TCTTGT-3′ (antisense), 5′-ACTCACCGTACCTGTAG
CCCTCATTTCCC-3′ [internal fluorescence-labeled
probe (FAM)] for murine CCR1; and 5′-CATGGCCT
TCCGTGTTCCTA-3′ (sense), 5′-ATGCCTGCTTCAC
CACC-TTCT-3′ (antisense), 5′-CCCAATGTGTCCGT
CGTGGATCTGA-3′ [internal fluorescence-labeled
probe (VIC)] for murine GAPDH. In some experiments
18S RNA was chosen as the internal standard, with
primers and probes purchased as predeveloped TaqMan
assay reagents. All primers and probes were obtained
from PE Biosystems. Specificity of the CCR1 primers
and probe was tested on plasmids containing sequences
of CCR1, CCR2, and CCR5.
Statistical analysis
Values are expressed as mean ± SEM or SD as indi-
cated. Statistical analysis was performed using SPSS 11.0
(SPSS Inc., Chicago, IL, USA). Significance of differences
was determined by the appropriate two-sided t test for
single comparisons. Analysis of variance (ANOVA) with
post hoc Bonferroni’s correction was used for multiple
comparisons. P values less than 0.05 were considered sta-
tistically significant.
RESULTS
Proteinuria and renal damage in adriamycin-treated mice
All mice that received two doses of 13 mg/kg adri-
amycin developed severe albuminuria within 2 weeks
after the first dose, with a further increase in urinary al-
bumin excretion at week 4, two weeks after the second
adriamycin injection, that persisted throughout the study
period until week 6 (Fig. 1A). The severe proteinuria
was accompanied by hypoproteinemia, hypoalbumine-
mia, and an increase of serum cholesterol levels (Fig. 1B),
consistent with the development of a nephrotic syn-
drome. There was also a tendency toward elevated values
of BUN (Fig. 1B) in adriamycin-treated mice compared
to saline-treated controls, but this difference did not reach
statistical significance (P = 0.077). Histology at 6 weeks
revealed the typical pathologic abnormalities seen in
FSGS. In most glomeruli there was a segmental to global
accumulation of hyaline matrix, with collapse of the asso-
ciated glomerular capillary loops (Fig. 2A to D). Quanti-
tative evaluation of the glomerulosclerosis demonstrated
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Fig. 1. Functional parameters in progressive
adriamycin (ADR) nephropathy. Persistent,
nephrotic-range proteinuria with decreased
serum protein levels, hypalbuminemia and
elevated serum cholesterol in adriamycin-
treated mice. (A) Urinary albumin excretion
was evaluated at day 0 and at week 2, 4, 6 after
the first adriamycin injection in adriamycin-
treated mice and saline-treated controls. (B)
Levels of total serum protein, serum albumin,
serum cholesterol, and blood urea nitrogen
(BUN) in adriamycin-treated mice and saline-
injected controls were determined at week
6. Values are expressed as means ± SEM.
∗P < 0.05, ∗∗P < 0.01, #P < 0.001 compared
to saline-treated.
a 2.7-fold increase of PAS-positive staining in glomeruli
of adriamycin-treated mice compared to saline-injected
controls, in which only glomerular basement membranes
stained positive (44.0% ± 2.1% versus 16.3% ± 0.3% P <
0.001) (Fig. 3A). Glomerular pathology was accompanied
by prominent tubulointerstitial changes, including tubu-
lar cell atrophy with brush border loss, tubular dilation,
intraluminal cast formation, and expansion of the inter-
stitial volume due to accumulation of mononuclear cells
and deposition of extracellular matrix (Fig. 2B and D).
Less frequently, glomeruli with minimal lesions embed-
ded in normal tubules could be found adjacent to severely
damaged areas, indicating the focal nature of the disease
process.
Immunohistochemical staining detected a prominent
accumulation of CD45+ leukocytes in interstitial lesions
of adriamycin-treated mice at 6 weeks (7.5 ± 0.2 cells/high
power field versus 0.3 ± 0.09 cells/high power field in
saline-treated controls) (P < 0.001) (Figs. 2E and F and
3B). This interstitial infiltrate consisted of ER-HR3+
macrophages (5.9 ± 0.2 cells/high power field versus 0.2 ±
0.08 cells/high power field) (P < 0.001) and CD3+ T cells
(3.0 ± 0.2 high power field versus 0.3 ± 0.03 cells/high
power field) (P < 0.001) (Figs. 2G and H and 3C and
D). In contrast, no glomerular leukocyte infiltration was
detected at 6 weeks after induction of the disease. The
accumulation of interstitial leukocytes was accompanied
by fibrotic lesions in the cortex. There was a significant
increase of interstitial FSP1+ fibroblasts (5.7 ± 0.3 cells/
high power field versus 0.4 ± 0.07 cells/high power field)
(P < 0.001) in cortical lesions of adriamycin-treated mice
at 6 weeks (Figs. 2I and J and 3E). Quantitative analysis
of silver-stained sections revealed an increase in the in-
terstitial volume index by 3.1-fold in adriamycin-treated
mice compared to saline-treated controls (19.2 ± 2.5 ver-
sus 6.1 ± 0.5) (P < 0.001) (Figs. 2K and L and 3F).
Expression of chemokines and the chemokine receptor
CCR1 in adriamycin nephropathy
As locally expressed chemokines mediate renal
leukocyte recruitment we investigated the expression
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Fig. 2. Severe glomerulosclerosis, tubular injury, interstitial leukocyte accumulation, and interstitial fibrosis in kidneys with adriamycin (ADR)
nephropathy at week 6. (A and C) Periodic acid-Schiff (PAS)-stained kidney sections of saline-treated contol mice showed normal renal morphology.
(B and D) Adriamycin-injected mice developed severe glomerular lesions with segmental to global sclerosis, indicated by PAS-positive glomerular
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Fig. 3. Morphometric analysis of glomerulosclerosis, interstitial leukocyte accumulation, and interstitial fibrosis in kidneys with adriamycin (ADR)
nephropathy compared to saline-treated controls at week 6. The degree of glomerulosclerosis (A), interstitial accumulation of CD45+ leukocytes
(B), ER-HR3+ macrophages (C), CD3+ lymphocytes (D), fibroblast-specific protein 1 (FSP1)+ fibroblasts (E), and interstitial volume expansion
(F) was analyzed as described in the Methods section. Values are expressed as means ± SD. ∗P < 0.001 compared to saline-treated.
of chemokines in kidneys of mice with adriamycin
nephropathy at 6 weeks. Whole-kidney mRNA samples
were subjected to a ribonuclease protection assay con-
taining probes for detection of the CC chemokines
CCL1/TCA-3, CCL2/MCP-1, CCL3/MIP-1a, CCL4/
MIP-1b , CCL5/RANTES, and CCL11/eotaxin (Fig. 4A
and B). All of these chemokines were up-regulated
in kidneys of adriamycin-treated mice compared to
saline-treated controls at week 6 (Fig. 4B). The mRNA
expression of the CCR1 ligands CCL3/MIP-1a and
CCL5/RANTES was increased by 11.5-fold and 3.5-fold,
respectively. In addition, we detected increased mRNA
levels of CCL2/MCP-1 (9.0-fold), CCL3/MIP-1b (10.8-
fold), and CCL11/eotaxin (5.6-fold). There was also a
small, but significant induction of CCL1/TCA-3 (1.3-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
deposits. Glomerular injury was accompanied by tubular damage with tubular dilation, intratubular cast formation, tubular cell atrophy, and necrosis.
There was a marked expansion of the interstitium with infiltration of mononuclear cells and matrix deposition. (E) Immunohistochemical staining
for CD45+ leukocytes in saline-treated control kidneys and (F) adriamycin-treated kidneys demonstrated a periglomerular and interstitial, but no
glomerular accumulation of leukocytes after adriamycin injection. (G) The interstitial leukocyte infiltrate in the cortex of adriamycin-treated mice
consisted of ER-HR3+ macrophages and (H) CD3+ lymphocytes. (I) Fibroblast-specific protein 1 (FSP1)+ cells were rarely detectable in control
kidneys. (J) In contrast, FSP1+ cells as markers for active fibrosis accumulated in the interstitium of kidneys with adriamycin nephropathy. (K)
Silver-stained cortical sections of control kidneys and (L) adriamycin-treated kidneys demonstrated interstitial volume expansion in adriamycin-
injected mice. (M) (In situ hybridization and (N) immunohistochemistry for CCL2/monocyte chemoattractant protein 1 (MCP-1) localized most
CCL2 expression to tubular epithelial cells (arrows), with some expression also present in the interstitial infiltrate (arrowhead). Note that CCL2
mRNA expression was clearly restricted to intact tubular cells, and did not occur in dilated tubules with flattened epithelium. (O) CCL5/RANTES
mRNA and (P) protein expression localized more prominently to interstitial infiltrates (arrowheads). CCL5 protein was also found in intact, but
not atrophic tubuli (arrows). CCL2 and CCL5 expression was absent in glomeruli. PAS stain (A to D); hematoxylin counterstain (E to J, N, and P);
silver staining (K and L); hematoxylin-eosin counterstain (M and O) [original magnifications ×200 (A, B, and E to P); ×400 (C and D).
fold) (Fig. 4B). To localize the chemokine mRNA ex-
pression within kidneys after adriamycin treatment we
performed in situ hybridization studies with antisense
probes for CCL2/MCP-1 and CCL5/RANTES on kid-
neys obtained from mice 6 weeks after the first adri-
amycin injection (Fig. 2M and O). CCL2 and CCL5
mRNA transcripts (black silver grains) both were abun-
dantly detected in the cortical tubulointerstitium, but
not in glomeruli of adriamycin-treated animals. CCL2
mRNA was prominently expressed in tubular epithelial
cells (Fig. 2M, arrows), and, to a lesser extent, in intersti-
tial cells. Tubular cells also expressed CCL5, but CCL5
mRNA was more abundantly detected in the interstitial
infiltrate (Fig. 2O, arrowheads). Of note, the tubular ex-
pression of chemokine mRNA (and protein) localized
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Fig. 4. Expression of proinflammatory chemokines and CCR1 in murine adriamycin (ADR) nephropathy at week 6. (A) mRNA expression of
multiple CC chemokines was increased in kidneys of adriamycin-treated mice compared to saline-treated controls at week 6 as detected by RNase
protection assay (RPA). A representative gel segment from three adriamycin-treated and two control kidneys is shown. (B) Chemokine mRNA
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cells. In contrast, CCR1 expression was not detectable in resting or lipopolysaccharide (LPS)-stimulated tubular epithelial cells. CCR1 expression
was also absent in primary renal fibroblasts, either unstimulated or transforming growth factor-b (TGF-b) stimulated.
to intact tubular epithelial cells, but was not found in
dilated tubules with flattened and atrophic epithelium
(Fig. 2M to P). In kidneys from saline-treated control
mice CCL2 and CCL5 transcripts were only occasionally
found in few interstitial cells (data not shown). No sig-
nals were detected with the use of CCL2 or CCL5 sense
sequence templates as a negative control. Immunostain-
ing for CCL2 (Fig. 2N) and CCL5 (Fig. 2P) localized
the proteins in a similar distribution as the respective
mRNA transcripts. Particularly, no significant glomeru-
lar staining for the two chemokines could be detected in
adriamycin-treated mice.
Because we intended to study effects of the CCR1 an-
tagonist BX471 in adriamycin nephropathy we first de-
termined the expression of CCR1 in this model. Using
real-time RT-PCR a 6.7-fold induction of CCR1 mRNA
expression could be detected in kidneys with adriamycin
nephropathy (Fig. 4B). Unfortunately, due to the lack of
appropriate antibodies and probes for in situ hybridiza-
tion cell-specific localization of renal CCR1 expression by
immunostaining or in situ hybridization is not feasible at
the moment. We therefore performed studies with leuko-
cyte subsets, a murine tubular epithelial cell line, and pri-
mary renal fibroblasts to identify cell types which express
CCR1, and therefore would be the potential target for
renal BX471 action in the kidney. Both macrophages and
CD4+ T cells isolated from spleens of BALB/c mice ex-
pressed CCR1 mRNA. Macrophages expressed CCR1
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at a 10-fold higher level than CD4+ T cells (Fig. 4C).
No CCR1 mRNA could be detected in renal tubular ep-
ithelial cells, with or without LPS stimulation (Fig. 4C).
Similarly, CCR1 mRNA expression was not detectable
in unstimulated or TGF-b–stimulated renal fibroblasts
(Fig. 4C). These results suggest that infiltrating mononu-
clear cells, in particular of the monocyte/macrophage lin-
eage, are the major source of renal CCR1 expression
in adriamycin nephropathy. In contrast, activated renal
tubular cells and interstitial fibroblasts do not express
CCR1 and therefore do not contribute to the renal CCR1
expression.
CCR1 blockade does not affect glomerulosclerosis and
proteinuria in adriamycin nephropathy
In order to study effects of the CCR1 blockade on the
progression of chronic FSGS rather than on its initiation,
treatment with the CCR1 antagonist BX471 was started
at the time of the second adriamycin injection at week 2,
when gross albuminuria was already present (Fig. 5A). At
this time point adriamycin-injected mice had already de-
veloped substantial glomerular pathology, as indicated by
deposition of PAS-positive material in the glomeruli. The
glomerular area with PAS-positive staining was 34.5% ±
3.5% in adriamycin-injected mice at week 2, compared
to 16.3% ± 1.7% in saline-injected controls (P < 0.001)
(Fig. 7A). Mice with established adriamycin nephropathy
received either vehicle solution or BX471 from week 2 to
6. In vehicle-treated mice there was a further increase in
the urinary albumin excretion from week 2 to 4, following
the second adriamycin injection, and this degree of albu-
minuria persisted until the end of the study period at week
6 (Fig. 5A). Mice that received BX471 instead of the ve-
hicle showed a similar response in the albuminuria, with-
out significant differences throughout the experimental
period (Fig. 5A). Consistent with the same degree of uri-
nary albumin loss there were no significant differences in
the serum values for total protein, albumin, and choles-
terol between vehicle-treated and BX471-treated mice
with adriamycin nephropathy at 6 weeks. Serum protein
and albumin levels decreased, and cholesterol levels in-
creased to a similar extent in both groups compared to
mice without adriamycin treatment, which received ei-
ther vehicle or BX471 from week 2 to 6 (Fig. 5B). The
latter two groups of mice served as controls and demon-
strated that neither treatment with the vehicle solution
nor BX471 allone (without injection of adriamycin) re-
sulted in albuminuria (Fig. 5A) or altered serum values
(Fig. 5B). BUN levels were not significantly different be-
tween all four groups of mice.
A similar degree of albuminuria in vehicle- and BX471-
treated mice suggested that treatment with the CCR1
antagonist did not alter the extent of glomerular damage
induced by the adriamycin injections. In both groups of
mice the extent of glomerular damage further increased
from week 2 to 6 (Figs. 6A and B and 7A). Consistent
with the functional data the extent of glomerulosclerosis
was similar in vehicle-treated and BX471-treated mice
on histologic evaluation of PAS-stained sections (Fig. 6A
and B). The glomerular area with PAS-positive staining
was 43.3% ± 1.8% and 44.3% ± 2.9% in vehicle-treated
and BX471-treated mice with adriamycin nephropathy,
respectively, without significant differences between the
two groups (Fig. 7A). In contrast, glomerular PAS stain-
ing was significantly lower in mice which received either
vehicle or BX471, but no adriamycin, and it was in a sim-
ilar range as in the saline-treated control mice at week 2
(Fig. 7A). Glomerular leukocyte infiltration was not seen
in any of the six groups of mice. In summary, these data
indicate that BX471, given from week 2 to 6, did not af-
fect the glomerular injury and the developing nephrotic
syndrome in adriamycin nephropathy.
CCR1 blockade reduces interstitial leukocyte
recruitment in adriamycin nephropathy
Adriamycin nephropathy is characterized by progres-
sive interstitial lesions consisting of immune cell infil-
trates, fibroblast accumulation, and matrix deposition.
As reported by Wang et al [14] in their original charac-
terization of the murine adriamycin nephropathy model
interstitial accumulation of macrophages appears to be
most prominent in early phases of the disease, with a
dramatic decrease in later stages. In contrast, a gradual
increase in the number of interstitial T lymphocyte infil-
trates was noted until week 6 [14]. As CCR1 is involved
in immune cell migration, we compared renal intersti-
tial leukocyte recruitment between BX471- and vehicle-
treated mice with adriamycin nephropathy. At 6 weeks,
BX471 treatment reduced the amount of CD45+ leuko-
cytes in interstitial lesions by 37% compared to vehicle-
treated mice with adriamycin nephropathy (4.6 ± 0.4
cell/high power field versus 7.3 ± 0.2 cells/high power
field) (P < 0.001) (Fig. 7B). Consistent with the previous
report [14] we found the most prominent macrophage in-
filtration in adriamycin-injected mice at week 2 (8.9 ± 1.9
ER-HR3+ cells/high power field), with a subsequent de-
crease in vehicle-treated control mice until week 6 (5.6 ±
0.2 cells/high power field) (P < 0.05) (Fig. 7C). Impor-
tantly, in this later phase BX471 treatment from week
2 to 6 significantly reduced the tubulointerstitial infiltra-
tion of macrophages by 51% compared to vehicle-treated
mice (2.7 ± 0.2 cells/high power field versus 5.6 ± 0.2 cells/
high power field) (P < 0.001) (Figs. 6C and E and 7C).
At week 2 significant numbers of interstitial CD3+ lym-
phocytes were present in adriamycin-injected mice (1.1 ±
0.2 cells/high power field), and these increased further in
vehicle-treated mice until week 6 (3.2 ± 0.6 cells/high
power field) (P < 0.05) (Fig. 7D). BX471 treatment re-
duced this gradual accumulation of interstitial CD3+
lymphocytes by 22% (2.5 ± 0.1 cells/high power field
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Fig. 5. BX471 treatment of mice with established adriamycin (ADR) nephropathy did not affect proteinuria and serum parameters. (A) Urinary
albumin excretion was evaluated at day 0 and at week 2, 4, and 6 in vehicle- or BX471-treated mice without or with induced adriamycin nephropathy.
(B) Levels of total serum protein, serum albumin, serum cholesterol, and blood urea nitrogen (BUN) in BX471- or vehicle-treated mice with or
without adriamycin nephropathy were determined at week 6. Values are expressed as means ± SEM. NS is not significant.
versus 3.2 ± 0.6 cells/high power field in BX471-treated
and vehicle-treated mice at 6 weeks, respectively) (P <
0.05), (Figs. 6E and F and 7D). Control mice, which did
not receive adriamycin, but were treated with vehicle or
BX471 alone, did not show leukocytic cell infiltrates in
the interstitial compartment (Fig. 7B to D). Taken to-
gether, these data demonstrate that CCR1 blockade with
BX471 reduced interstitial recruitment of macrophages
and lymphocytes in adriamycin nephropathy.
CCR1 blockade reduces interstitial fibrosis in adriamycin
nephropathy
As a cellular marker of fibrosis the amount of FSP1+
fibroblasts was assessed by immunohistochemistry in
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Fig. 6. Glomerulosclerosis, interstitial leukocyte accumulation, and interstitial fibrosis in vehicle- or BX471-treated mice with adriamycin (ADR)
nephropathy at week 6. Periodic acid-Schiff (PAS)-stained kidney sections from vehicle-treated mice (A) and BX471-treated mice (B) revealed
a similar degree of glomerulosclerosis after adriamycin injections. Interstitial infiltration of ER-HR3+ macrophages in vehicle-treated mice with
adriamycin nephropathy (C) was reduced in BX471-treated mice (D). Interstitial CD3+ lymphocytes were more abundant in vehicle-treated
ADR mice (E) than in BX471-treated mice (F). The accumulation of fibroblast-specific protein 1 (FSP1)+ fibroblasts in interstitial lesions of
vehicle-treated adriamycin mice (G) was more prominent than in BX471-treated mice (H). Silver staining revealed a more severe expansion of
the interstitial volume in vehicle-treated mice with adriamycin nephropathy (I) compared to the BX471-treated group (H) [original magnifications
×400 (A through J)].
interstitial lesions of vehicle- and BX471-treated mice
with adriamycin nephropathy. The progressive accumu-
lation of fibroblasts from week 2 (2.9 ± 0.8 cells/high
power field) to week 6 (5.3 ± 0.2 cells/high power field in
vehicle-treated mice) (P < 0.05) was completely blocked
in BX471-treated mice (2.8 ± 0.1 cells/high power field)
(P < 0.001 compared to vehicle-treated controls), re-
sulting in a 48% reduction of fibroblast accumulation
in BX471-treated mice at week 6 (Figs. 6G and H
and 7E). Furthermore, BX471 treatment reduced the
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Fig. 7. Morphometric analysis of glomerulosclerosis, interstitial leukocyte accumulation, and interstitial fibrosis in vehicle- or BX471-treated mice
with adriamycin (ADR) nephropathy at week 6. The degree of glomerulosclerosis (A), interstitial accumulation of CD45+ leukocytes (B), ER-
HR3+ macrophages (C), CD3+ lymphocytes (D), fibroblast-specific protein (FSP1)+ fibroblasts (E), and interstitial volume expansion (F) was
analyzed in saline- or adriamycin-treated mice at week 2 (when BX471 treatment was started) and in vehicle- or BX471-treated mice with adriamycin
nephropathy at week 6. As control groups, vehicle- or BX471-treated mice without adriamycin injections were also evaluated. Values are expressed
as means ± SD. NS is not significant.
progressive interstitial volume expansion from week 2
(interstitial volume index 8.0 ± 1.0) to week 6 (17.6 ±
1.6 in vehicle-treated controls) (P < 0.001) by 23%
(13.6 ± 2.7 in BX471-treated mice) (P < 0.05 compared
to vehicle-treated controls) (Figs. 6I and J and 7F). No
changes in interstitial cell counts or morphometric pa-
rameters were observed in vehicle- or BX471-injected
control mice without adriamycin treatment (Fig. 7B to
F). Thus, BX471 treatment significantly reduced not only
the interstitial leukocyte influx, but also the extent of in-
terstitial fibrosis in mice with adriamycin nephropathy.
DISCUSSION
In the kidney, the extent of interstitial leukocyte in-
filtration and tubulointerstitial fibrosis are strong prog-
nostic factors for the progression to ESRD, independent
of the primary glomerular or interstitial lesion [1, 5].
We have previously shown that interstitial expression of
the proinflammatory chemokine receptors CCR1, CCR2,
and CCR5 on leukocyte infiltrates and their respective
chemokine ligands is induced in various models of pro-
gressive renal injury, including obstructive nephropathy
after unilateral ureteral ligation and immune complex
2276 Vielhauer et al: CCR1 blockade in FSGS
nephritis in MRL lpr/lpr mice [21, 23]. Therefore, inter-
fering with renal leukocyte recruitment (e.g., by block-
ing CCR1) might reduce the inflammatory response in
the kidney and prevent the progression of renal fibro-
sis [24]. We used adriamycin-induced nephropathy in
mice as a model of FSGS to examine whether BX471,
a small molecule CCR1 antagonist, may reduce renal
leukocyte recruitment and subsequent interstitial fibro-
sis, a hypothesis supported by our results. These find-
ings are of particular relevance to the potential thera-
peutic role of CCR1 antagonism in progressive human
nephropathies, as the adriamycin-induced glomeru-
losclerosis and subsequent interstitial inflammation and
fibrosis resembles the course of glomerular and intersti-
tial changes in human chronic proteinuric renal disease
[14].
CCR1 blockade with BX471 has been shown to inhibit
leukocyte adhesion and transmigration through endothe-
lium in a dose-dependent manner under conditions of
shear flow in vitro [25, 26]. In the obstructive nephropa-
thy model we have recently shown that CCR1 blockade
with BX471 reduced the amount of leukocyte infiltra-
tion into the renal interstitium [11]. It might appear that
the report of worsening of glomerulonephritis in CCR1-
deficient mice with nephrotoxic serum nephritis would
be in contrast to these findings [13]. However, in these
mice an enhanced Th1 immune response was noted, so
that CCR1 deficiency might result in an overall change
in the immune response toward the nephrotxic serum,
altering the initiation of the disease [13]. Here, we used
adriamycin nephropathy as a model of progressive renal
disease induced by a nonimmune-mediated glomerular
injury. We found CCR1 to be prominently expressed in
kidneys during adriamycin nephropathy, and renal ex-
pression of multiple proinflammatory chemokines was
up-regulated, including the CCR1 ligands CCL3/MIP-
1a and CCL5/RANTES. Our results clearly demonstrate
that CCR1 blockade with BX471 in the advanced stage
of this model reduced renal interstitial leukocyte re-
cruitment and progression of renal fibrosis. These ob-
servations are consistent with the beneficial effects of
CCR1 blockade on the extent of leukocyte infiltration
and disease outcome in other models, including obstruc-
tive nephropathy [11], renal and heart transplantation
[27, 28], pulmonary fibrosis [12], and experimental en-
cephalomyelitis [25, 29]. Together these data argue for an
important role of CCR1-mediated leukocyte recruitment
into the tubulointerstitium in vivo. Surprisingly CCR1
blockade had no measurable effect on glomerular pathol-
ogy and proteinuria, indicating different mechanisms for
leukocyte infiltration of the glomerulus and tubulointer-
stitium.
BX471 treatment most effectively reduced the accu-
mulation of interstitial macrophages, being consistent
with the known expression of CCR1 on blood mono-
cytes and tissue macrophages. CCR1 and responsiveness
to its ligand CCL3/MIP-1a is up-regulated on human
monocytes upon transition to the macrophage phenotype
[30], and CCR1 mediates human monocyte adhesion and
transendothelial migration under flow [26]. Furuichi et
al [8] analyzed CCR1 expression in glomerular and in-
terstitial lesions of human nephropathies by immunohis-
tochemistry. These investigators noted that most CCR1-
positive cells in the interstitium were macrophages, and
that no CCR1 expression was detectable in intrinsic renal
cells. Moreover, the number of CCR1-positive cells in the
interstitium correlated with the intensity of interstitial fi-
brosis [8]. We found an abundant expression of CCR1
on splenic macrophages isolated from BALB/c mice, but
not on tubular epithelial cells or primary renal fibroblasts.
Taken together, these data suggest that circulating mono-
cytes and/or infiltrating renal macrophages are a major
cellular target of the CCR1 blockade by BX471. There
was also a decreased accumulation of CD3+ lymphocytes
in interstitial lesions of adriamycin mice, albeit less promi-
nent than the reduction in macrophages. This may relate
to the lesser expression of CCR1 mRNA demonstrated in
splenic CD4+T cells. Therefore, the decreased interstitial
T cell accumulation in BX471-treated mice might be ei-
ther the consequence of a direct antagonism of CCR1 ex-
pressed on infiltrating T cells, or an effect secondary to the
decreased interstitial macrophage infiltration with subse-
quent down-regulation of the inflammatory response in
the interstitium.
The reduced interstitial leukocyte infiltration was as-
sociated with a reduction of fibrosis in interstitial lesions
of BX471-treated mice with adriamycin nephropathy.
BX471 treatment from week 2 to 6 completely prevented
any further accumulation of interstitial fibroblasts, with-
out reversal of the already increased numbers present
at week 2. The progressive expansion of the intersti-
tial volume, which could already be noted at week 2
and increased until week 6, was significantly diminished
in BX471-treated mice, but could not be completely
prevented. We did not find any CCR1 mRNA expres-
sion in tubular epithelial cells or fibroblasts. This ar-
gues against a direct BX471 effect on CCR1 signaling
in epithelial-mesenchymal transformation or fibroblast
activation. It is most likely that the reduction of infil-
trating mononuclear cells in response to BX471 treat-
ment caused less fibroblast proliferation and activation.
Leukocytes, and particularly macrophages, secrete profi-
brotic cytokines such as TGF-b , platelet-derived growth
factor, basic fibroblast growth factor, connective tissue
growth factor, and platelet activating factor, which me-
diate epithelial-mesenchymal transformation, fibroblast
proliferation, and matrix synthesis [4, 31]. This inter-
pretation is consistent with our previous findings in the
obstructive nephropathy model demonstrating a similar
reduction of mononuclear cell infiltrates and subsequent
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interstitial fibrosis by BX471 [11]. Similar effects of CCR1
blockade were also reported in bleomycin-induced pul-
monary fibrosis with reduced mononuclear cell infiltrates
and collagen deposition in the lung, and an improvement
of survival [12]. The beneficial effects of BX471 in the
interstitium of adriamycin nephropathy are particularly
interesting in view of the severe proteinuria, which was
not affected by BX471 treatment. The persistent protein-
uria should provide a sustained stimulus for tubular cell
activation, which may result in secretion of chemokines
and profibrotic cytokines [32]. However, our data show
that persistent proteinuria per se was insufficient to fully
promote interstitial fibrosis when the interstitial infiltra-
tion of leukocytes was reduced in BX471-treated mice.
BX471 treatment had no effects on the degree of
glomerular damage induced by adriamycin, as functional
and histologic parameters were not different in vehicle-
or BX471 treated mice with adriamycin nephropathy.
A direct cytotoxic effect of adriamycin on podocytes is
thought to induce the initial glomerular damage. The pro-
gressive glomerulosclerosis is unlikely to be caused by a
toxic effect of chronic accumulation of adriamycin be-
cause adriamycin is rapidly cleared from blood and kid-
ney [33, 34]. The progressive glomerular sclerosis may re-
late to podocyte damage resulting in a self-perpetuating
process. These and any potential immunologic mecha-
nisms leading to the progressive glomerular injury af-
ter adriamycin are apparently independent of CCR1, as
its blockade had no beneficial effects on the glomeru-
lar lesions and proteinuria. Consistently with this view
we could not detect any significant glomerular infiltra-
tion of leukocytes at week 2 and 6. In addition, we could
not detect glomerular expression of the chemokines
CCL2/MCP-1 or CCL5/RANTES in adriamycin mice at
6 weeks, which is in marked contrast to prominent ex-
pression of these chemokines in the tubulointerstitial
compartment. Taken together, these data indicate that
the beneficial effects of BX471 are restricted to sites
of recruitment of CCR1-positive leukocytes. Further-
more, they provide evidence for different mechanisms of
glomerular and tubulointerstitial disease processes and
inflammatory leukocyte influx in these compartments.
CONCLUSION
Blockade of CCR1 with BX471 substantially reduced
interstitial leukocyte accumulation and subsequent renal
fibrosis in a murine model of FSGS with progressive in-
terstitial injury. This occurred in spite of persistent pro-
teinuria and glomerular damage. These findings suggest
a role for CCR1 in leukocyte recruitment to the inter-
stitium and a role of these CCR1-positive leukocytes in
the progressive renal interstitial fibrosis. CCR1 blockade
may therefore represent a promising therapeutic strategy
also in chronic proteinuric nephropathies that progress to
ESRD.
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